Literature DB >> 16305584

Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge.

Heather S Tomlinson1, Sarah A Corlett, Martin B Allen, Henry Chrystyn.   

Abstract

AIMS: Methods to determine the lung delivery of inhaled bronchodilators from metered dose inhalers include urinary drug excretion 30 min post inhalation and methacholine challenge (PD20). We have compared these two methods to differentiate lung delivery of salbutamol from metered dose inhalers using different inhalation methods.
METHODS: In phase 1 of the study, on randomized study days, 12 mild asthmatics inhaled placebo, one and two 100 microg salbutamol doses from a breath actuated metered dose inhaler, in randomized fashion on different days. In phase 2, they inhaled one 100 microg salbutamol dose from a metered dose inhaler using a SLOW (20 l min(-1)) and a FAST (60 l min(-1)) inhalation technique and a slow inhalation delayed until after they had inhaled for 5 s (LATE). Urinary excretion of salbutamol (0-30 min) and PD20 were measured after each dose.
RESULTS: Following placebo, one and two 100 microg salbutamol doses, the geometric mean for PD20 was 0.10, 0.41 and 0.86 mg respectively and the mean (SD) urinary drug excretion after one and two doses was 2.25 (0.65) and 5.37 (1.36) microg, respectively. After SLOW, FAST and LATE inhalations the geometric mean for PD20 was 0.50, 0.40 and 0.42 mg, respectively, and mean (SD) salbutamol excretion was 2.67 (0.84), 1.90 (0.70) and 2.72 (0.67) microg, respectively. Only the amount of drug excreted during the FAST compared with the SLOW and LATE inhalations showed a statistical difference (95% confidence interval on the difference 0.12, 1.54 and 0.06, 1.59 microg, respectively).
CONCLUSIONS: Urinary salbutamol excretion but not PD20 showed differences between the inhalation methods used. When using a metered dose inhaler slow inhalation is better and co-ordination is not essential if the patient is inhaling when they actuate a dose of the drug.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16305584      PMCID: PMC1884885          DOI: 10.1111/j.1365-2125.2005.02499.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation.

Authors:  H S Tomlinson; S A Corlett; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

2.  Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer.

Authors:  B J Lipworth; D J Clark
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

3.  Adverse reactions to the non-drug constituents of nebuliser solutions.

Authors:  R Beasley; P Rafferty; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

4.  A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers.

Authors:  Peter S Creticos; Wallace P Adams; Brent G Petty; Lionel D Lewis; Gur Jai Pal Singh; Arouna P Khattignavong; Justina A Molzon; Marilyn N Martinez; Paul S Lietman; Roger L Williams
Journal:  J Allergy Clin Immunol       Date:  2002-11       Impact factor: 10.793

5.  The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction.

Authors:  D Giannini; A Di Franco; E Bacci; F L Dente; M Taccola; B Vagaggini; P Paggiaro
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

6.  Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects.

Authors:  P J Barnes; N B Pride
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

7.  Improvement of pressurised aerosol deposition with Nebuhaler spacer device.

Authors:  S P Newman; A B Millar; T R Lennard-Jones; F Morén; S W Clarke
Journal:  Thorax       Date:  1984-12       Impact factor: 9.139

8.  Reproducibility and comparison of responses to inhaled histamine and methacholine.

Authors:  E F Juniper; P A Frith; C Dunnett; D W Cockcroft; F E Hargreave
Journal:  Thorax       Date:  1978-12       Impact factor: 9.139

9.  Relative lung and total systemic bioavailability following inhalation from a metered dose inhaler compared with a metered dose inhaler attached to a large volume plastic spacer and a jet nebuliser.

Authors:  V L Silkstone; S A Corlett; H Chrystyn
Journal:  Eur J Clin Pharmacol       Date:  2002-01       Impact factor: 2.953

10.  Effect of aerosol fenoterol on the severity of bronchial hyperreactivity in patients with asthma.

Authors:  C M Salome; R E Schoeffel; K Yan; A J Woolcock
Journal:  Thorax       Date:  1983-11       Impact factor: 9.139

View more
  8 in total

Review 1.  Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?

Authors:  John B Warren
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

2.  Controller Inhalers: Overview of Devices, Instructions for Use, Errors, and Interventions to Improve Technique.

Authors:  Patrick K Gleeson; Scott Feldman; Andrea J Apter
Journal:  J Allergy Clin Immunol Pract       Date:  2020-03-12

3.  Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers.

Authors:  Sagar S Bachhav; Poonam Sheth; Dennis Sandell; Mårten Svensson; Sharvari Bhagwat; Denise S Conti; Oluwamurewa Oguntimein; Sneha Dhapare; Bhawana Saluja; Lawrence Winner; Jürgen B Bulitta; Guenther Hochhaus
Journal:  AAPS J       Date:  2021-12-07       Impact factor: 4.009

4.  Evaluation of proficiency in using different inhaler devices among intern doctors.

Authors:  Ravish M Kshatriya; Nimit V Khara; Rajiv P Paliwal; Satish N Patel
Journal:  J Family Med Prim Care       Date:  2016 Apr-Jun

5.  ATTACHED, DETACHED and WITHOUT inhaler technique coaching tools to optimize pMDI use competence, asthma control and quality-of-life in asthmatic adults.

Authors:  Wesam G Ammari; Nathir M Obeidat; Abed Rahman Anani; Reem J AlKalbani; Mark Sanders
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895

6.  The Bioavailability of Salbutamol in Urine via Volumatic and Nonvolumatic Valved Holding Chambers.

Authors:  Fanak Fahimi; Farzad Kobarfard; Jamshid Salamzadeh; Atefeh Fakharian; Pegah Abdolahi; Azita Hajhossein Talasaz; Hamid Mahboobi Pour; Shadi Baniasadi; Mohammadreza Masjedi
Journal:  World Allergy Organ J       Date:  2011-11-18       Impact factor: 4.084

7.  Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.

Authors:  Fabien Pillard; Michel Lavit; Valérie Lauwers Cances; Jacques Rami; Georges Houin; Alain Didier; Daniel Rivière
Journal:  Respir Res       Date:  2015-12-24

Review 8.  Asthma management with breath-triggered inhalers: innovation through design.

Authors:  Mário Morais-Almeida; Helena Pité; João Cardoso; Rui Costa; Carlos Robalo Cordeiro; Eurico Silva; Ana Todo-Bom; Cláudia Vicente; José Agostinho Marques
Journal:  Asthma Res Pract       Date:  2020-06-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.